Life Sciences

  • December 15, 2025

    Ohio Gov. To Designate Synthetic Kratom Extract Illegal Drug

    Ohio Gov. Mike DeWine is looking to immediately ban synthetic kratom compounds while simultaneously seeking to either ban or heavily regulate the active ingredient in "natural kratom," citing serious public health concerns.

  • December 15, 2025

    Formula Suits An 'Undue Burden' On Cook County, Panel Says

    An Illinois appellate court Friday agreed with Abbott Laboratories that 23 lawsuits alleging the company failed to warn of important risks associated with infant formulas and caused premature babies to develop necrotizing enterocolitis should not have been filed in Cook County, where the infants at the center of those cases were not born and have never lived.

  • December 15, 2025

    USPTO Replaces Denver Office With Center In Montana

    Montana has been picked by the U.S. Patent and Trademark Office to be the first state to oversee community outreach in the area formerly serviced by the now-shuttered Rocky Mountain Regional Outreach Office in Denver.

  • December 15, 2025

    Cencora Pays $5B For Majority Stake Of OneOncology

    Pharmaceutical company Cencora Inc. unveiled plans Monday to acquire a majority stake in cancer care company OneOncology for $5 billion, buying interest from private equity shop TPG in a deal built by three law firms.

  • December 15, 2025

    Connecticut 'Likely' To Settle Generic Drug Price Cap Dispute

    A pharmaceutical industry trade group and the state of Connecticut have signaled their intent to settle a feud over the interpretation of the state's generic drug price cap law, and a federal judge gave them until Monday to say more about their plan.

  • December 15, 2025

    Fed. Circ. Won't Revive Bard Patents In AngioDynamics Row

    The Federal Circuit on Monday refused to revive claims in C.R. Bard patents on implanted catheter receptacles that were challenged by AngioDynamics, backing a Delaware federal court's finding that the claims were anticipated.

  • December 15, 2025

    Blank Rome Hires Baker McKenzie Litigator In DC

    Blank Rome LLP has hired a Baker McKenzie litigator who focuses his practice on technology, life sciences, aerospace, government contracts and energy industry-related matters to join the team in Washington, D.C., as a partner, the firm announced Monday.

  • December 15, 2025

    The Top Patent Decisions Of 2025

    The Federal Circuit decided its first en banc utility patent case in years and expanded who can use the U.S. International Trade Commission, while both the appeals court and U.S. Patent and Trademark Office took on the eligibility of AI patents. Here's a look at the top patent decisions of 2025.

  • December 15, 2025

    PTAB Creates New Prehearing Conference For AIA Reviews

    The Patent Trial and Appeal Board has rolled out a change to its trial practice guide that will create a new prehearing conference 15 days prior to oral hearings under the America Invents Act in cases implemented by the U.S. Patent and Trademark Office director.

  • December 15, 2025

    High Court Won't Review Doctor 'Upcoding' Acquittal Decision

    The U.S. Supreme Court said Monday that it won't review a decision allowing a retrial of a Maryland doctor who was initially found guilty of a COVID-19 testing scheme but then secured an acquittal.

  • December 15, 2025

    Supreme Court Declines Cannabis Ban Review

    The U.S. Supreme Court on Monday declined to hear a case challenging the federal marijuana ban, leaving in place a high court precedent that has governed cannabis policy for 20 years.

  • December 15, 2025

    Supreme Court Turns Down Entresto Patent Fight

    The U.S. Supreme Court on Monday rejected a petition from MSN Pharmaceuticals Inc. claiming the Federal Circuit improperly applied what is known as after-arising technology when reviving a patent covering Novartis Pharmaceuticals Corp.'s blockbuster cardiovascular drug Entresto.

  • December 15, 2025

    McDermott-Led Sobi To Buy US Gout Specialist For $1.5B

    Swedish biopharma company Swedish Orphan Biovitrum AB said Monday that it has agreed to acquire Arthrosi Therapeutics Inc., a specialist in treatment for gout, for up to $1.5 billion in a deal guided by McDermott.

  • December 12, 2025

    1st Circ. OKs Barring Medicaid Planned Parenthood Coverage

    A First Circuit panel on Friday upheld the Trump administration's ban on Medicaid funding for Planned Parenthood, vacating a lower court's order that would've kept in place Medicaid reimbursements for Planned Parenthood clinics in 22 states.

  • December 12, 2025

    Ore. Justices Rule Docs Can Be Liable For Nonpatient Deaths

    Oregon's highest court ruled that medical professionals can be held liable if their negligence results in a nonpatient's death, settling a split between a trial and appeals court in a case over a cyclist struck and killed by a driver under the influence of prescription drugs.

  • December 12, 2025

    Squires Institutes 7 AIA Reviews, Denies 12 Other Petitions

    U.S. Patent and Trademark Office Director John Squires has instituted seven America Invents Act reviews in the second round of cases where he has found that patent challenges warrant consideration since taking over the institution process.

  • December 12, 2025

    CooperSurgical Escapes Repeat Filshie Clip Claims In Conn.

    Medical device maker CooperSurgical Inc. has scored a quick win on some women's claims that the Filshie Clip, a coated titanium birth control device, detached and migrated within their bodies, with a Connecticut state judge finding certain plaintiffs could not advance cases similar to claims they lost elsewhere.

  • December 12, 2025

    Mississippi Litigator Joins Butler Snow From Adams & Reese

    Butler Snow LLP announced that an experienced litigation and appellate attorney has joined the firm's healthcare practice in Ridgeland, Mississippi, after a stint with Adams & Reese LLP.

  • December 12, 2025

    Fed. Circ. Says PTAB Was Right To Ax Tracking Patent Claims

    The Federal Circuit on Friday refused to revive claims in a group of patents for tracking items during surgeries and other uses, rejecting challenges to how the Patent Trial and Appeal Board interpreted key claim terms.

  • December 12, 2025

    Higgs Fletcher Forms White Collar, Regs Enforcement Team

    San Diego-based law firm Higgs Fletcher & Mack LLP has launched a white collar crime and regulatory enforcement defense practice group, citing heightened regulatory scrutiny in the financial and healthcare sectors and rising enforcement risks for licensed professionals and institutions.

  • December 11, 2025

    LA Bellwether Jury To Decide If J&J Hid Talc Risk For Decades

    An attorney for one of two women who claim Johnson & Johnson's talcum products caused their ovarian cancer told a California jury Thursday in a bellwether trial's closing arguments that the company hid the health risks of talc for decades, while the company's attorney insisted the science is on their side.

  • December 11, 2025

    DC Circ. Oversees FDA Fight Over Generic IBS Drug

    Norwich Pharmaceuticals faced off against the U.S. Food and Drug Administration before the D.C. Circuit twice Thursday morning, both battles part of the drugmaker's five-year effort to bring a generic version of a prescription antibiotic used to treat irritable bowel syndrome to market.

  • December 11, 2025

    Tracking Challenges To USPTO's Discretion Policy

    Leaders at the U.S. Patent and Trademark Office have significantly altered the Patent Trial and Appeal Board playing field since March, making changes to institution reviews that have led to unprecedented levels of petition denials. A steady stream of companies has challenged those changes through mandamus petitions to the Federal Circuit, and here Law360 tracks where those petitions stand.

  • December 11, 2025

    Pharmacies Battle For Coverage Of Opioid Lawsuit Claims

    Publix Super Markets and a Georgia-based generic-drug wholesaler urged the Eleventh Circuit on Thursday to force their insurers to defend them in numerous lawsuits accusing the pharmacies of improperly distributing opioids, arguing their policies' coverage for "bodily injury" should include the suits.

  • December 11, 2025

    NC County Sues DuPont, 3M, Tyco Over PFAS Contamination

    A county in southeastern North Carolina is suing 3M Co., DuPont de Nemours Inc., the Chemours Co., Tyco Fire Products LP and other companies, alleging that they knowingly sold products containing PFAS, or "forever chemicals," that have contaminated county land.

Expert Analysis

  • Adapting To A Plaintiff-Side Mindset For Patent Monetization

    Author Photo

    A recent decrease in risk for patent owners at the U.S. Patent and Trademark Office, combined with increased corporate interest in monetizing patent assets, creates an attractive case for evaluating patents from a plaintiff-side mindset, but in-house counsel transitioning from a defense-side mindset to a plaintiff-side mindset should study certain considerations, says Kate Tellez at Steptoe.

  • AI Evidence Rule Tweaks Encourage Judicial Guardrails

    Author Photo

    Recent additions to a committee note on proposed Rule of Evidence 707 — governing evidence generated by artificial intelligence — seek to mitigate potential dangers that may arise once machine outputs are introduced at trial, encouraging judges to perform critical gatekeeping functions, say attorneys at Lankler Siffert & Wohl.

  • Series

    The Law Firm Merger Diaries: Getting The Message Across

    Author Photo

    Communications and brand strategy during a law firm merger represent a crucial thread that runs through every stage of a combination and should include clear messaging, leverage modern marketing tools and embrace the chance to evolve, says Ashley Horne at Womble Bond.

  • Opinion

    Horizontal Stare Decisis Should Not Be Casually Discarded

    Author Photo

    Eliminating the so-called law of the circuit doctrine — as recently proposed by a Fifth Circuit judge, echoing Justice Neil Gorsuch’s concurrence in Loper Bright — would undermine public confidence in the judiciary’s independence and create costly uncertainty for litigants, says Lawrence Bluestone at Genova Burns.

  • 10 Commandments For Agentic AI Tools In The Legal Industry

    Author Photo

    Though agentic artificial intelligence has demonstrated significant promise for optimizing legal work, it presents numerous risks, so specific ethical obligations should be built into the knowledge base of every agentic AI tool used in the legal industry, says Steven Cordero at Akerman LLP.

  • Fed. Circ. In Oct.: Spotlight On Wording Beyond Patent Claims

    Author Photo

    The Federal Circuit's recent decision in Barrette Outdoor Living v. Fortress Iron provides useful guidance on how patent prosecutors should avoid language that triggers specification disclaimer and prosecution disclaimer, doctrines that may be used to narrow the scope of patent infringement claims, say attorneys at Knobbe Martens.

  • New Drug Ad Regs Could Lead To A Less Informed Public

    Author Photo

    A federal push to mandate full safety warnings in pharmaceutical advertising could make drug ads less appealing for companies to air, which in turn could negatively affect consumers' health decisions by removing an accessible information source, say Punam Keller at Dartmouth College and Ceren Canal Aruoba at Berkeley Research Group.

  • Series

    Preaching Makes Me A Better Lawyer

    Author Photo

    Becoming a Gospel preacher has enhanced my success as a trial lawyer by teaching me the importance of credibility, relatability, persuasiveness and thorough preparation for my congregants, the same skills needed with judges and juries in the courtroom, says Reginald Harris at Stinson.

  • A Look At Middlemen Fees In 340B Drug Discount Program

    Author Photo

    A U.S. Senate committee's recent hearing on the Section 340B drug discount program, along with statistical analysis of payment amounts, contribute to a growing consensus that middlemen fees are too high, say William Sarraille at the University of Maryland, and Shanyue Zeng and Rory Martin at IQVIA.

  • How Large Patent Damages Awards Actually Play Out

    Author Photo

    Most large verdicts in patent infringement cases are often overturned or reduced on appeal, implying that the Federal Circuit is serving its intended purpose of correcting outlier outcomes, and that the figures that catch headlines and dominate policy debates may misrepresent economic realities, says Bowman Heiden at Berkeley School of Law.

  • Series

    Law School's Missed Lessons: Practicing Client-Led Litigation

    Author Photo

    New litigators can better help their corporate clients achieve their overall objectives when they move beyond simply fighting for legal victory to a client-led approach that resolves the legal dispute while balancing the company's competing out-of-court priorities, says Chelsea Ireland at Cohen Ziffer.

  • Navigating 2025's Post-Grant Proceeding Shakeups

    Author Photo

    Extensive changes to the U.S. Patent Trial and Appeal Board's post-grant proceedings this year, including the new settled expectations factor and revitalization of Fintiv factors, require petitioners and patent owners alike to be mindful when selecting patents to assert and challenge, say attorneys at Quinn Emanuel.

  • Series

    The Law Firm Merger Diaries: How To Build On Cultural Fit

    Author Photo

    Law firm mergers should start with people, then move to strategy: A two-level screening that puts finding a cultural fit at the pinnacle of the process can unearth shared values that are instrumental to deciding to move forward with a combination, says Matthew Madsen at Harrison.

  • Latisse Ruling's Lessons On Avoiding Chemical Patent Pitfalls

    Author Photo

    The Federal Circuit's decision in Duke v. Sandoz, reversing a $39 million infringement claim for selling a generic Latisse product, reinforces a fundamental truth in chemical patent strategy: Broad genus claims rarely survive without clear evidence of possession of specific embodiments, says Kimberly Vines at Stites & Harbison.

  • Considerations When Invoking The Common-Interest Privilege

    Author Photo

    To successfully leverage the common-interest doctrine in a multiparty transaction or complex litigation, practitioners should be able to demonstrate that the parties intended for it to apply, that an underlying privilege like attorney-client has attached, and guard against disclosures that could waive privilege and defeat its purpose, say attorneys at DLA Piper.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.